Brokers and banks usually stop taking bids earlier. Check the exact time with yours.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Repayment of borrowings
Prepayment or repayment of certain outstanding borrowings availed by the company.
Expansion of manufacturing facility
Funding capital expenditure requirements towards setting up a new manufacturing facility to expand production capacity.
General corporate purposes
Funding general corporate requirements and issue related expenses.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Bio Medica Laboratories Limited, incorporated in 2015, is an Indian pharmaceutical manufacturing company based in Indore, Madhya Pradesh. The firm specializes in the development and contract manufacturing of pharmaceutical parenteral formulations, covering both liquid injectables and dry powder injectables for human and veterinary applications. The company operates specialized production facilities equipped with Good Manufacturing Practices and Good Laboratory Practices certifications granted by regulatory authorities in Madhya Pradesh. Its business model is structured primarily around a B2B framework, serving as a contract development and manufacturing partner to pharmaceutical marketing firms and institutional healthcare suppliers across India. Bio Medica Laboratories maintains a diversified portfolio of formulation capabilities, supported by dedicated quality control laboratories and processing lines. The proceeds from its initial public offering were directed toward expanding manufacturing infrastructure at its existing site and reducing existing debt obligations to support long term growth.
No anchor investors added yet.
Source: RHP • Analysis provided for informational purposes
Last Updated: 24 August 2026, 5:24 PM
Certified Parenteral Manufacturing Infrastructure
The company operates specialized production facilities with Good Manufacturing Practices and Good Laboratory Practices certifications for liquid and dry powder injectables.
Established B2B Business Model
Its contract manufacturing framework provides long term relationships with domestic pharmaceutical marketing firms and healthcare distributors.
Dual Healthcare Coverage
Product lines span both human healthcare formulations and veterinary injectables, broadening overall operational addressable market.
Client Concentration Sensitivity
A significant portion of total revenue relies on key B2B contract manufacturing clients, making earnings sensitive to client retention.
Raw Material Price Volatility
Fluctuations in active pharmaceutical ingredient costs and chemical inputs can impact operating margins.
Regulatory Compliance Vulnerabilities
Any non-compliance with quality requirements or delay in drug license renewals could interrupt manufacturing activities.
Bio Medica Laboratories Limited
Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate, Indore, Madhya Pradesh, 452015
View on Maps →Skyline Financial Services Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.